Coronavirus Highlights: India Reports 170 Fresh Cases, Active Cases At 2,371
Coronavirus Highlights: Follow this page for all the latest updates on coronavirus from India and around the world.
Mumbai on Monday reported four COVID-19 cases, which took the tally here to 11,55,161, while the death toll stood unchanged at 19,746. Two recoveries left the metropolis with 31 active cases. s per BMC data, the recovery rate was 98.3 per cent and the caseload doubling time stood at 2,18,345 days.
170 fresh cases of coronavirus infections were reported on Monday, while the active cases declined by 52 to reach 2,371.
According to the Union Health Ministry data updated at 8 am Monday, the total number of cases is now 4.46 crore (4,46,80,094).
Two fresh cases of Covid-19 were reported in the last 24 hours in Thane raising its tally of infections to 7,47,410, a health official said on Monday.
The new cases were reported on Sunday, he said.
There are currently 11 active COVID-19 cases in the district, the official said.
Over 1,000 social media accounts --- some with millions of followers --- that criticised Chinese government's covid policy were taken down, reported IANS.
Social media platform Weibo said it had suspended or banned accounts for what it described as personal attacks against Chinese Covid specialists, The BBC reported.
Weibo did not specify which posts had prompted the action.
Serum Institute of India's Covovax vaccine will get approval as booster dose in next 10-15 days, said SII chief Adar Poonawalla, adding that it works very well against the Omicron variant of the coronavirus, reported PTI.
"Covovax will be approved as a booster in the next 10-15 days. It is actually the best booster because it works very well against Omicron, more than Covishield," said Poonawalla while speaking to reporters on the sidelines of an event at Pune's Bharti Vidyapeeth University.
When asked about states and districts not getting Covishield vaccine, Poonawalla said that the Union government has ample stocks for supply.
Background
Coronavirus Highlights: Hello and welcome to ABP Live. Follow ABP Live's Covid blog to get the latest developments, breaking news, the latest updates, and other developing stories across the country and abroad.
India logged 228 new coronavirus infections, while the active cases declined to 2,503, according to the Union Health Ministry data updated on Friday.
The Covid case tally was recorded at 4.46 crore (4,46,79,547).
The death toll stands at 5,30,714, with four deaths. Two deaths were reconciled by Kerala while one death each was reported from Bihar and Uttarakhand in last 24 hours, the data updated at 8 am stated.
The daily positivity was recorded at 0.11 per cent while the weekly positivity was pegged at 0.12 per cent.
The active cases comprise 0.01 per cent of the total infections, while the national COVID-19 recovery rate has increased to 98.80 per cent, the ministry said.
A decrease of 51 cases has been recorded in the active COVID-19 caseload in a span of 24 hours.
Meanwhile, Serum Institute of India chief executive officer Adar Poonawalla on Sunday said its Covovax vaccine will get approval as a booster in the next 10 to 15 days, adding it works very well against the Omicron variant of coronavirus.
Speaking to reporters on the sidelines of an event at Bharti Vidyapeeth University here, Poonawalla, when asked about states and districts not getting Covishield vaccines, said there are ample stocks with the Union government for supply.
"Covovax will be approved as a booster in the next 10-15 days. It is actually the best booster because it works very well against Omicron, more than Covishield," said Poonawalla.
He said everyone was looking at India, not just in terms of healthcare but because the country managed to take care of a huge and diverse population and also helped 70 to 80 nations during the COVID-19 pandemic.
"This was all possible because of the leadership of our Central government, our state governments, healthcare workers, manufacturers, all of whom worked together with one common goal," he said.
- - - - - - - - - Advertisement - - - - - - - - -